RE:Oramed and Premis Biotech Announce use Pill and Spray Trial https://www.oramed.com/oramed-forms-a-joint-venture-oravax-medical-inc-for-the-development-of-novel-oral-covid-19-vaccines/
Oravax’s COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus. The oral delivery of the vaccine should allow for widescale inoculation and easier distribution of the vaccine without requiring an injection.
In a pilot animal study, the oral COVID-19 vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA).
Oravax anticipates commencing a clinical study during the second quarter of 2021.
_____________________________________
No published data on what animal study they are referring to?
Trueflame wrote:
- Did KLY get ran over by these 2 firms or are they just not mentioning KLY or Claritas on purpose?
- Oravax announced that a COVID-19 vaccine in tablet form could begin early clinical trials soon.
"We need human studies to be sure," he said.
Other types of second-generation vaccines are being investigated, such as vaccines delivered by a spray through the nose.
https://www.businessinsider.com/oravax-tablet-covid-19-vaccine-plans-trials-soon-no-needles-2021-3